Back to Search Start Over

Tumour necrosis factor plays a deleterious role in the pathogenesis of chikungunya virus infection.

Authors :
Moreira TP
Sousa CDF
Melo Costa VR
Queiroz-Junior CM
Santos FM
Bonilha CS
Ésper LM
Nogueira ML
Cunha TM
Teixeira MM
Costa VV
de Souza DDG
Source :
Immunology [Immunology] 2023 Mar; Vol. 168 (3), pp. 444-458. Date of Electronic Publication: 2022 Nov 14.
Publication Year :
2023

Abstract

Arthralgia is a hallmark of chikungunya virus (CHIKV) infection and can be very debilitating and associated with a robust local inflammatory response. Many pathophysiological aspects associated with the disease remain to be elucidated. Here, we describe a novel model of CHIKV infection in immunocompetent mice and evaluate the role of tumour necrosis factor in the pathogenesis of the disease. C57BL/6 wild type (WT) or TNF receptor 1 deficient (TNFR1 <superscript>-/-</superscript> ) mice were inoculated with 1 × 10 <superscript>6</superscript> PFU of CHIKV in the paw. Alternatively, etanercept was used to inhibit TNF in infected WT mice. Hypernociception, inflammatory and virological analysis were performed. Inoculation of CHIKV into WT mice induced persistent hypernociception. There was significant viral replication in target organs and local production of inflammatory mediators in early time-points after infection. CHIKV infection was associated with specific humoral IgM and IgG responses. In TNFR1 <superscript>-/-</superscript> mice, there was a decrease in the hypernociception threshold, which was associated with a milder local inflammatory response in the paw but delayed viral clearance. Local or systemic treatment with etanercept reduced CHIKV-induced hypernociception. This is the first study to describe hypernociception, a clinical correlation of arthralgia, in immunocompetent mice infected with CHIKV. It also demonstrates the dual role of TNF in contributing to viral clearance but driving tissue damage and hypernociception. Inhibition of TNF may have therapeutic benefits but its role in viral clearance suggests that viral levels must be monitored in CHIKV-infected patients and that TNF inhibitors should ideally be used in combination with anti-viral drugs.<br /> (© 2022 John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2567
Volume :
168
Issue :
3
Database :
MEDLINE
Journal :
Immunology
Publication Type :
Academic Journal
Accession number :
36164989
Full Text :
https://doi.org/10.1111/imm.13583